Cargando…

Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine

The global threat of COVID-19 is continued with no commercially available vaccine or drug yet. While the application of convalescent therapy is usually beneficial, for critically ill patients, the detrimental effect associated with some antibodies is also reported. The immunoglobulin G (IgG) antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Andualem, Henok, Kiros, Mulugeta, Getu, Sisay, Hailemichael, Wasihun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532904/
https://www.ncbi.nlm.nih.gov/pubmed/33062618
http://dx.doi.org/10.2147/ITT.S274746
_version_ 1783590023027752960
author Andualem, Henok
Kiros, Mulugeta
Getu, Sisay
Hailemichael, Wasihun
author_facet Andualem, Henok
Kiros, Mulugeta
Getu, Sisay
Hailemichael, Wasihun
author_sort Andualem, Henok
collection PubMed
description The global threat of COVID-19 is continued with no commercially available vaccine or drug yet. While the application of convalescent therapy is usually beneficial, for critically ill patients, the detrimental effect associated with some antibodies is also reported. The immunoglobulin G (IgG) antibody in response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is described, albeit the lack of defining whether the difference in subclasses has a beneficial or detrimental role. IgG2 has limited ability to activate innate immune cells and complement-mediated inflammation, which have been inversely described in SARS-CoV-2 pathogenesis. The expansion of IgG2 is promoted by interferon γ (IFN-γ); however, there is a low level of IFN-γ in COVID-19 patients. Therefore, this review describes the importance of targeting IgG2, with IFN-γ in minimizing the SARS-CoV-2 associated inflammation, and may provide insight into the design of vaccine or antibody-based therapies to COVID-19 disease.
format Online
Article
Text
id pubmed-7532904
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75329042020-10-14 Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine Andualem, Henok Kiros, Mulugeta Getu, Sisay Hailemichael, Wasihun Immunotargets Ther Review The global threat of COVID-19 is continued with no commercially available vaccine or drug yet. While the application of convalescent therapy is usually beneficial, for critically ill patients, the detrimental effect associated with some antibodies is also reported. The immunoglobulin G (IgG) antibody in response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is described, albeit the lack of defining whether the difference in subclasses has a beneficial or detrimental role. IgG2 has limited ability to activate innate immune cells and complement-mediated inflammation, which have been inversely described in SARS-CoV-2 pathogenesis. The expansion of IgG2 is promoted by interferon γ (IFN-γ); however, there is a low level of IFN-γ in COVID-19 patients. Therefore, this review describes the importance of targeting IgG2, with IFN-γ in minimizing the SARS-CoV-2 associated inflammation, and may provide insight into the design of vaccine or antibody-based therapies to COVID-19 disease. Dove 2020-09-29 /pmc/articles/PMC7532904/ /pubmed/33062618 http://dx.doi.org/10.2147/ITT.S274746 Text en © 2020 Andualem et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Andualem, Henok
Kiros, Mulugeta
Getu, Sisay
Hailemichael, Wasihun
Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title_full Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title_fullStr Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title_full_unstemmed Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title_short Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine
title_sort immunoglobulin g2 antibody as a potential target for covid-19 vaccine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532904/
https://www.ncbi.nlm.nih.gov/pubmed/33062618
http://dx.doi.org/10.2147/ITT.S274746
work_keys_str_mv AT andualemhenok immunoglobuling2antibodyasapotentialtargetforcovid19vaccine
AT kirosmulugeta immunoglobuling2antibodyasapotentialtargetforcovid19vaccine
AT getusisay immunoglobuling2antibodyasapotentialtargetforcovid19vaccine
AT hailemichaelwasihun immunoglobuling2antibodyasapotentialtargetforcovid19vaccine